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ABSTRACT:
The biological programs of vertebrates exhibit a remarkable degree of functional 
degeneracy, adaptive compensation and robustness, to preserve homeostasis 
and generate reproducible phenotypic outputs irrespective of variations in signal 
strength,  noise  and  quality.  Cancers  are  difficult  to  treat  not  only  because  they 
are so mechanistically diverse but also because they adapt or evolve in response 
to any pharmacological elective pressure we impose upon them. Hence, an ideal 
cancer drug target would exert a function both necessary for cancer cell survival 
and functionally non-redundant, rendering it impossible for tumor cells to 
compensate for, or evolve independence from, the inhibitory effect of any drug 
aimed at that target. In this review, we discuss the unique, non-degenerate and 
highly pleiotropic role played by Myc in coordinating, engaging and maintaining 
the diverse intracellular and extracellular programs required for cell proliferation 
in vivo. These properties make Myc a compelling candidate cancer drug target, 
at least in principle: an assertion recently reinforced by new in vivo genetic data.
WHY ARE CANCERS DIFFICULT TO 
CURE?
Cancers are extremely multifarious diseases that 
arise through the accumulation in somatic cells of 
mutations in the genes that regulate and restrain cell 
multiplication, survival, repair, movement and invasion. 
The process is “Darwinian” – oncogenic mutations occur 
at random and fate of the mutant cells and their progeny 
is determined by their relative “fitness” – in this case, 
their relative capacities to survive and propagate in and, 
eventually, spread from, their requisite somatic niche. 
While the mutations that fuel tumor evolution occur 
randomly, their evolutionary tradjectories are shaped 
by the selective pressures that normally limit untoward 
somatic cell growth – principally the restricted and 
tightly regulated availability of mitogenic and survival 
signals, barriers to cell migration and macroscopic 
tumor expansion, and the relentless vigilance of innate 
tumor suppressor pathways. Not surprisingly, given the 
haphazard and aleatory way in which individual cancers 
evolve, each cancer in each patient is unique. Indeed, it is 
now clear that there is a substantial genetic diversity even 
within tumor cell populations in each individual tumor. 
Such innate genetic diversity feeds the engines of further 
evolution – in essence, each tumor must be treated as an 
evolving species rather than as a unitary object. 
Many point to this alarming genetic diversity in 
cancers – an inevitable consequence of the haphazard 
and directionless way that each cancer evolves, as the 
principal reason why cancers have proven so difficult to 
treat. The idea is that past cancer therapies were applied 
fairly indiscriminately against many different genetic 
pathologies and what is needed is a therapy that is 
tailored to the particular complement of genetic lesions 
in each individual’s cancer – cancer therapy will need to 
be personalized. With the advent of new-targeted drugs, 
engineered to inhibit specific defects in specific cancers 
types, many hope that this may, at least, be feasible. 
However, this disregards a more fundamental reason for 
intractability of cancers, which is that cancer cells adapt 
and evolve. Biological ”wetwear” is inherently noisy and 
protean and works reliably only because it has evolved 
to be robust. Such robustness involves a great deal of 
functional redundancy, intrinsic error correction and 
inherent self-organization. Targeting a biological system Oncotarget 2011; 2:   1307 - 1313 1308 www.impactjournals.com/oncotarget
with a drug is just another source of noise and variability 
and, if it is able, the system spontaneously compensates, 
re-routing signals and restoring homeostasis. Then, in 
those rare situations where compensation is insufficient, 
evolution takes over: spontaneously arising mutant cancer 
clones resistant to the targeted drug rapidly outgrow their 
incapacitated siblings and the patient relapses. The chilling 
truth is that it doesn’t matter how effective/ specific a 
therapy is – if its target function can be circumvented by 
compensation or evolution, that therapy will inevitably 
fail – clinically, it is just a matter of when.
ROBUSTNESS AND SWITCHABILITY 
IN TUMORS AND THEIR 
MICROENVIRONMENT
Can anything be done to gainsay two such 
formidable adversaries as compensation and adaptation? 
One appealing strategy has been to limit the capacity for 
evolution of resistance by targeting the genetically normal 
and stable stromal compartment of tumors rather than 
genetically unstable cancer cells themselves. Expansion 
and maintenance of macroscopic tumors are dependent on 
their somatic microenvironment, a complicated melange 
of  stromal,  vascular  and  inflammatory  cell  types  that 
provides necessary oxygen, nutrients, and survival factors. 
This obligate role played by the genetically stable tumor 
microenvironment in macroscopic tumor maintenance has 
spurred a variety of novel therapeutic approaches aimed at 
neutralizing tumor cell-nonautonomous components of the 
tumor mass, such as tumor vasculature and inflammation. 
Unfortunately, the effectiveness of such therapies is 
thwarted by the highly robust and functionally degenerate 
nature of the extracellular programmes that maintain the 
tumor microenvironment, making them highly adaptive - 
inhibition of one node triggers homeostatic compensatory 
re-routing through others [1-4]. Such functional 
redundancy, together with the highly interdependent and 
reciprocal relationship between tumor cells and their 
microenvironment, involving interactions with diverse 
stromal, vascular and inflammatory cell types, makes it 
difficult to dissect out the cause-and-effect dependencies 
linking the two and, consequently, where best to intervene 
for optimal therapeutic benefit. 
An alternative potential strategy for thwarting cancer 
cell compensation and evolution is to identify therapeutic 
targets that are essential for the survival of cancer cells 
but are not functionally redundant and whose inhibition, 
therefore, cannot be circumvented by compensation or 
evolution. Do such targets exist? Can we make drugs 
that inhibit them? How bad might the side effects of such 
therapies be, given that such central engines of biology are 
likely to serve important functions in many normal cells 
and tissues? These become the critical questions.
MYC AS A FUNCTIONALLY NON-
REDUNDANT NODE IN GROWTH 
SIGNALING 
The robustness of biological programs is a 
prerequisite for self-organizing homeostasis and for the 
generation of reproducible phenotypic outputs even when 
the signals directing such outputs are variable, noisy and 
capricious. Such robustness is manifest in the remarkable 
capacity of biological systems to resist and correct for 
perturbation and to rebuild after damage. Nonetheless, 
biological systems must also have the capacity to drive 
binary decisions – cells either arrest or proliferate, live or 
die, remain a progenitor or differentiate, stay put or move. 
How can the capacity to execute unequivocal decisions 
be accommodated with a biology that has evolved to 
resist perturbation? We suggest that these two antithetical 
imperatives are reconciled by connecting functionally 
degenerate, robust networks with functionally non-
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Figure 1: Schematic model of how the need for 
robustness in biological systems is reconciled with 
the need for binary switchability. The consolidated 
outputs from robust, self-correcting and functionally degenerate 
information-gathering and information-processing “clouds” 
(e.g. receptor tyrosine kinases, intracellular kinases, disparate 
coordinated programs mediating somatic cell replication and 
propagation) are hypothesized to funnel down into functionally 
non-degenerate, go/no go switches such Ras, Myc and the 
activating E2F (E2F1, 2 & 3a) proteins. The obligate and 
functionally non-degenerate properties of Myc, Ras and E2F 
make them a unique class of therapeutic drug target, whose 
inhibition cannot easily be circumvented by compensatory or 
evolutionary mechanisms. However, the very essentialness of 
these targets raises the specter of severe side effects. In this 
regard, Myc has the advantage that, since its sole biological role 
appears to be in cell proliferation, the only side effects of Myc 
inhibition are likely to affect regenerating tissues.Oncotarget 2011; 2:   1307 - 1313 1309 www.impactjournals.com/oncotarget
degenerate network nodes. In this way, the net outputs 
of diffuse, robust networks are distilled into binary Go/
No-go decisions. This idea is depicted for cell growth 
signaling in Figure 1: the consolidated outputs from 
highly degenerate information gathering and information 
processing effector “clouds” (e.g. ligated receptor 
tyrosine kinases, intracellular kinases, proliferation 
genes) are funneled into functionally non-degenerate 
nodes such as Ras, Myc and mitogenic E2F (E2F1, 2 & 
3a), whose activities serve to commit information flow 
down to the next functionally robust and degenerate cloud 
of effectors. When it comes to treating such a protean 
and evolutionarily adaptable pathology as cancer, such 
ubiquitously essential and functionally non-redundant 
nodes are especially intriguing pharmacological targets. 
In this review, we consider the potential of inhibiting Myc 
as a general treatment for cancers. 
Myc is a basic helix–loop–helix leucine zipper 
transcription factor that coordinates the diverse 
transcriptional programs necessary for cell growth, 
proliferation, invasion, expansion and angiogenesis, as 
well as a variety of protective checkpoint mechanisms 
such as growth arrest and apoptosis [5-7]. Myc’s highly 
pleiotropic effects are mirrored by its enormous range 
of gene targets. Expression array, SAGE, chromatin IP, 
promoter scanning and whole cell proteomic approaches 
indicate thousands of Myc target genes with roles in 
virtually every aspect of cell and tissue behavior [8-17]. 
Myc is present at very low levels in normal cells; both 
the short-lived c-Myc protein and its equally short-lived 
mRNA are tightly and continuously dependent upon 
external mitogens.
Because of the unique and pivotal role that only Myc 
can fill in coordinating the transcription of its thousands 
of target genes, Myc is functionally non-redundant. 
And while there are three discrete members of the Myc 
transcription factor family (of which at least two, c-Myc 
and N-Myc, appear largely isofunctional), most adult cells 
rely solely on c-Myc to integrate the transcription of their 
proliferative programs. By contrast, N-Myc and L-Myc 
are restricted to various stages of tissue development, 
although recently it has become evident that N-Myc, and 
perhaps L-Myc, are expressed in stem and progenitor 
compartments of both normal and neoplastic adult tissues. 
c-Myc null mice fail to develop beyond embryonic day 
9.5  [18]  while  Rat1  fibroblasts  (which,  incidentally, 
express neither N-myc or L-myc) in which both copies of 
the c-myc gene have been ablated by targeted homologous 
recombination exhibit greatly reduced rates of RNA, 
protein translation and protein degradation and profoundly 
slowed proliferation, with severe defects at multiple 
points in the cell cycle [19]. These observations indicate 
that, in effect, Myc serves as the unique, functionally non-
redundant node that relays diverse upstream intracellular 
mitogenic signals to the legion of downstream genetic 
programs that implement cell proliferation (Figure 1).
Intriguingly, Myc is deregulated and/or overexpressed 
in the majority of cancers, where it hijacks the same diverse 
intracellular and extracellular regenerative programs that 
drive normal somatic cell expansion. Ectopic activation of 
c-Myc alone is usually insufficient to drive tumorigenesis 
without the cooperation of additional sporadic oncogenic 
lesions, in great part because elevated Myc expression 
is a potent trigger of apoptosis [20-25], one of several 
intrinsic tumor suppressive mechanisms that antagonizes 
the neoplastic potential of dominant oncogenes [26]. It 
may be for this reason that oncogenic activation of Myc 
is infrequently a driving lesion in cancers, at least in 
early stage tumors. Rather, Myc expression is typically 
deregulated and elevated due to oncogenic mutations in 
upstream signaling pathways that relentlessly and inaptly 
drive endogenous Myc expression. 
The in vivo oncogenic impact of deregulated Myc 
has been explored in detail using a variety of switchable 
transgenic mouse models in which regulatable forms 
of Myc, expressed at high level, have been targeted to 
specific tissues. Using a conditional form of Myc fused 
to a modified hormone binding domain of the estrogen 
receptor (MycERTAM) that is responsive only to the synthetic 
steroid 4-hydroxytamoxifen (4-OHT) [27], activation of 
Myc alone was shown to trigger rapid proliferation and 
disruption of differentiation when targeted to suprabasal 
keratinocytes in vivo, resulting in dramatic papillomatosis 
that rapidly regressed upon subsequent inactivation of 
MycERTAM [28]. Intriguingly, sustained Myc activation 
was,  alone,  sufficient  to  induce  not  only  epidermal 
cell expansion but also the rapid and dramatic onset of 
dermal angiogenesis in regions adjacent to the Myc-
driven papillomas in great part, due to the elevated levels 
of VEGF secreted by Myc-expressing keratinocytes. 
Such angiogenesis is continuously dependent on Myc 
activity since subsequent Myc de-activation triggers 
abrupt vascular collapse and regression of papillomas 
[28]. In a different switchable Myc transgenic model, 
acute activation of MycERTAM  in  pancreatic  β  cells  in 
vivo triggered rapid and wholesale β cell proliferation: 
in this case, however, β cell expansion was curtailed by 
concomitant  induction  of  β  cell  apoptosis,  resulting  in 
net islet attrition. Nonetheless, when such apoptosis was 
blocked by co-expression of the apoptosis inhibitor Bcl-
xL, Myc activation triggered sustained and progressive β 
cell expansion, rapidly leading to the formation of large, 
locally  invasive,  inflammatory  and  highly  angiogenic 
β  cell  tumors  [29].  The  rapidity  and  synchrony  with 
which such Myc-driven β cell neoplasms acquire such 
ostensibly diverse neoplastic attributes indicates that all 
such traits are directly instructed by Myc, and not the 
result of subsequent mutations [29]. Moreover, just as 
in skin, subsequent c-Myc deactivation triggered rapid 
and complete regression of islet tumors, accompanied Oncotarget 2011; 2:   1307 - 1313 1310 www.impactjournals.com/oncotarget
by collapse of tumor vasculature and microenvironment. 
Several  similar  studies  in  other  tissues  confirm  that, 
in most cases, sustained Myc expression is required to 
maintain Myc-driven tumors [30-33], although there 
are occasional exceptions to this due to compensatory 
activation of alternate oncogenic signaling pathways 
[34]. In such instances, Myc de-induction is accompanied 
by growth arrest, terminal differentiation and vascular 
collapse. Indeed, even brief inactivation of Myc appears 
to offer potential therapeutic value [35-37], fueling the 
contemporary concept of “oncogene addiction” – an 
hypothesized acquired dependency in which tumor 
cells become dependent on the aberrantly sustained flux 
running through the oncogenic lesions. Given the capacity 
of Myc to drive and maintain both angiogenesis and local 
inflammation  and  stromal  remodeling,  at  least  some 
of this dependency appears to be due to collapse of the 
tumor microenvironment when oncogenic Myc is turned 
off [38].
Indeed, a detailed kinetic expression array analysis 
following acute activation and subsequent deactivation 
of Myc in pancreatic β cells revealed a clear and direct 
instructive role for Myc in initiating and maintaining 
the sustaining interplay between tumor cells and their 
microenvironment [39]. Acute activation of c-Myc was 
found to trigger expression and release of interleukin 
1β (IL-1β), a pleiotropic cytokine implicated in acute 
and  chronic  inflammation  and  a  potent  inducer  of 
metalloproteinase activity. This, in turn, triggered the 
release of pre-existing, extracellular matrix-bound VEGF, 
liberating it to bind its cognate receptor on endothelial 
cells,  and  thereby  flicking  the  angiogenic  switch  [40]. 
c-Myc activation also triggers the rapid induction of a 
cluster of chemokines that likely mediate recruitment to the 
tumor site of various inflammatory cells, including mast 
cells, macrophages and neutrophils [39]. A subsequent 
study demonstrated that mast cell recruitment is essential 
for macroscopic tumor expansion and maintenance of 
tumor vasculature [41]. Thereafter, a mutually supportive, 
reciprocal interaction develops between the Myc-driven β 
tumor cells that is necessary for growth and maintenance 
of tumors and requires continuous Myc activity for its 
maintenance. 
MYC AS A TARGET FOR CANCER 
THERAPY
Such studies indicate the pivotal role that oncogenic 
Myc plays in driving and maintaining multiple aspects 
of the tumor environment, including angiogenesis, 
stromal remodeling, tumor invasion, and recruitment of 
inflammatory  pathways.  However,  as  already  pointed 
out, the majority of human tumors are not driven by 
Myc mutations but by “upstream” activated oncogenes 
mutations in most cancers lie “upstream” in RTKs, Ras, 
Wnt or a host of other signaling pathways. In such tumors, 
the role played by endogenous Myc in tumor induction, 
progression and maintenance has, until recently, remained 
unclear. A study by Baudino et al. indicated a more 
general, physiological role for Myc in angiogenesis - 
c-Myc–/–  embryos  exhibit  deficits  in  vasculogenesis, 
angiogenesis and primitive erythropoiesis and have 
reduced expression of VEGF and the angiogenic factor 
angiopoietin-2 as well as elevated levels of the angiogenic 
inhibitors thrombospondin-1 and angiopoietin-1 in murine 
embryonic stem cells and yolk sacs [42]. More recently, the 
role played by endogenous Myc, as opposed to ectopically 
activated oncogenic Myc, in the maintenance of cancers 
driven by other oncogenic mechanisms, addressed the 
extent to which endogenous Myc acts as a common 
downstream conduit of the upstream oncogenic signals 
that drive most human cancers. To do this, a dominant 
interfering mutant of Myc, Omomyc, was employed 
that displaces Myc’s obligate endogenous partner Max 
and thereby prevents Myc from transactivating its target 
genes via its concensus E-box elements [43-45]. By 
placing systemic Omomyc expression under the control 
of doxycyline, Myc function may be reversibly blocked 
globally in all tissues in vivo. Systemic inhibition of 
Myc in both the well-established LSL–KrasG12D murine 
model of non-small cell lung cancer [46] and the 
RIP1-Tag2  model of pancreatic insulinomas driven by 
SV40 T/t antigens [47] triggered rapid and wholesale 
regression of incipient and established tumors [48] [49], 
confirming  that  endogenous  Myc  function  is  required 
for maintenance of tumors driven by diverse oncogenic 
mechanisms. A careful kinetic analysis of Myc-inhibition-
induced tumor regression in the RIP1-Tag2  model 
demonstrated that inhibition of endogenous Myc triggers 
the rapid collapse of the tumor microenvironment, with 
concomitant apoptosis of endothelial cells, suppression 
of all detectable interaction between VEGF and its 
receptor, inhibition of both recruitment and/or retention 
of the inflammatory cells macrophages and neutrophils, 
vascular collapse and hypoxia [49, 50]. Moreover, such 
collapse of the tumor microenvironment temporally 
preceeds death of tumor cells or detectable regression of β 
cell tumor masses, strongly suggesting that collapse of the 
tumor microenvironment is a cause, not a consequence, of 
tumor regression. Furthermore, regression of RIP1-Tag2 
tumors occurs with identical kinetics and gross pathology 
when endogenous Myc is inhibited solely in the β cell 
compartment,  confirming  that  it  is  endogenous  Myc, 
within the tumor cells themselves, that is responsible for 
establishing and maintaining the signal cross-talk between 
tumor and microenvironment [49].
As discussed, the ideal cancer drug target must fulfill 
an essential function that is continuously required for 
tumor maintenance but dispensable (at least in the short 
term) for maintenance and function of any normal tissues. 
For optimal therapeutic efficacy, the target should also be 
functionally non-redundant – in that way, its inhibition Oncotarget 2011; 2:   1307 - 1313 1311 www.impactjournals.com/oncotarget
cannot be circumvented by adaptation, compensation 
or evolution. Finding such targets, should they exist, 
remains the most pressing problem in contemporary 
translational cancer research. In many ways Myc looks 
like  it  fulfills  all  the  above  criteria:  it  acts  as  a  non-
redundant downstream node through which all upstream 
oncogenic and mitogenic signals pass, relaying those 
signals on the diverse genes that implement the complex 
and coordinated process of cell proliferation. It is essential 
for effective cell proliferation and, because its actions 
appear broadly limited to cell proliferation, the spectrum 
of side effects caused by its systemic inhibition is likely 
to be limited only to proliferating tissues. Unfortunately, 
several factors continue to diminish enthusiasm for 
pharmacological targeting of Myc. First,  Myc exerts 
its manifold effects mostly through protein-protein 
interactions, an unfashionable and often difficult class of 
biological process to perturb with small molecule drugs, 
although recent advances in tethering and macrolide 
chemistries now make this more feasible. Second, aberrant 
Myc expression in most human cancers is usually not due 
to mutation in the Myc gene itself but a consequence 
of its induction by ‘upstream’ oncogenic signals. The 
therapeutic utility of inhibiting Myc when its aberrant 
expression is a consequence, not a cause, of oncogenesis 
is unclear. Third, Myc is essential for proliferation and 
stem cell compartment maintenance of regenerative adult 
tissues such as the gastrointestinal tract, skin and bone 
marrow. Hence, blocking Myc function systemically 
might trigger unacceptably severe side effects, suppressing 
proliferation in those same tissues that are vulnerable 
to classical chemo- and radiotherapy. Finally, if Myc is 
required solely for cell proliferation, at best its inhibition 
is likely to cause tumor cell arrest, not death, and as such 
would have limited therapeutic utility. Together, such 
concerns have greatly undermined the credibility of Myc 
inhibition as an anti-cancer strategy.
Surprisingly, however, the genetic studies in mice in 
which Myc function is systemically inhibited [48] offer 
us a great deal of reassurance. Although systemic Myc 
inhibition induces profound growth suppression in adult 
proliferating tissues – effectively stalling proliferation 
in regenerative tissues such as intestine, bone marrow, 
skin and testis – it is remarkably well tolerated for 
extended periods, in great part because Myc inhibition 
does not elicit any disruption of tissue integrity. Mice 
exhibit no signs of distress and maintain their weight 
and normal blood chemistry. Moreover, the side effects 
of systemic myc inhibition on all normal tissues are 
completely reversible upon restoration of endogenous 
Myc function [48]. Yet more surprisingly, given its lack 
of toxicity in normal proliferating tissues, Myc inhibition 
has an unexpectedly potent cytotoxic impact on tumor 
cells, triggering rapid and complete regression of both 
K-RasG12D-driven non-small cell lung cancer [48] and 
of SV40 large T/small t antigen-driven pancreatic islet 
tumors in RIP1-Tag2 mice [49], irrespective of stage 
of the tumor progression. At least part of the basis for 
this  unanticipated  tumor  specificity  is  that  sustained 
Myc activity is required by tumor cells to maintain the 
continuous  output  of  angiogenic  and  pro-inflammatory 
factors needed to maintain the peculiarly factor-dependent 
microenvironment needed to support solid tumors: hence, 
Myc inhibition rapidly triggers the collapse of the tumor 
microenvironment. Of note, out of literally hundreds of 
individual lung tumors in the KRasG12D-driven NSCLC 
mouse model, no tumors resistant to Myc inhibition 
have ever emerged (Soucek & Evan, unpublished data), 
consistent with the unique, essential non-redundant role 
that Myc plays: tumor cells cannot circumvent their need 
for Myc by compensation or evolution. It is also, perhaps, 
telling that, out of several hundred individual β-cell RIP1-
Tag2 tumors, each comprised of many thousands of tumor 
cells in which both Rb and p53 had been simultaneously 
incapacitated, the only occasional tumors that emerged 
as resistant to doxycycline had all lost expression of the 
omomyc transgene [49]. Hence, the only mechanism by 
which tumors can circumvent Omomyc inhibition of Myc 
is to “break” the model system. This is an exception that 
seems to prove the rule that Myc is obligate for tumor 
survival.
These observations strongly support the candidacy of 
Myc as a therapeutic target in many, most, or even (given 
its universal role in normal and tumor cell proliferation) 
all cancers. Although pharmacological inhibition of Myc 
currently remains a pipe dream such studies indicate that 
there are, indeed, common, essential and functionally 
non-degenerate cancer targets. Hopefully, advances in 
drug design and implementation will some day soon allow 
us to drug the undruggable and offer renewed therapeutic 
hope to cancer patients. 
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